MALCOLM BRENNER to Tumor Cells, Cultured
This is a "connection" page, showing publications MALCOLM BRENNER has written about Tumor Cells, Cultured.
Connection Strength
0.689
-
The clone ranger? Mol Ther. 2008 Sep; 16(9):1520-1.
Score: 0.068
-
Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40(+) and CD40(-) plasmacytoma cells. Blood. 2002 Jul 01; 100(1):200-7.
Score: 0.044
-
Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood. 2002 Mar 15; 99(6):2009-16.
Score: 0.043
-
Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer. 2001 Oct 15; 94(2):228-36.
Score: 0.042
-
Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells. A model for immunotherapy. Exp Hematol. 2001 Aug; 29(8):952-61.
Score: 0.041
-
Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma. Cancer Gene Ther. 2001 May; 8(5):378-87.
Score: 0.041
-
Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector. Hum Gene Ther. 2000 Jul 01; 11(10):1477-88.
Score: 0.038
-
Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum Gene Ther. 1998 Jun 10; 9(9):1303-11.
Score: 0.033
-
Antitumor responses induced by transgenic expression of CD40 ligand. Hum Gene Ther. 1997 Nov 01; 8(16):1935-43.
Score: 0.032
-
A novel herpes vector for the high-efficiency transduction of normal and malignant human hematopoietic cells. Blood. 1997 Jan 01; 89(1):119-27.
Score: 0.030
-
Immunomodulatory effects of human neuroblastoma cells transduced with a retroviral vector encoding interleukin-2. Cancer Gene Ther. 1994 Dec; 1(4):253-8.
Score: 0.026
-
Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication. Br J Cancer. 1993 May; 67(5):933-8.
Score: 0.023
-
Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med. 1993 Jan 01; 177(1):213-8.
Score: 0.023
-
Malignant plasma cells are sensitive to LAK cell lysis: pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma. Br J Haematol. 1990 Aug; 75(4):499-505.
Score: 0.019
-
Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies. Lancet. 1988 Apr 30; 1(8592):969-71.
Score: 0.017
-
CD45 monoclonal antibody-mediated cytolysis of human NK and T lymphoma cells. Haematologica. 2006 Jul; 91(7):886-94.
Score: 0.015
-
E1A-induced apoptosis does not prevent replication of adenoviruses with deletion of E1b in majority of infected cancer cells. Cancer Gene Ther. 2004 Sep; 11(9):585-93.
Score: 0.013
-
Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Mol Ther. 2003 Jun; 7(6):748-54.
Score: 0.012
-
Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells. Hum Gene Ther. 2003 Apr 10; 14(6):545-59.
Score: 0.012
-
Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells. Cancer Res. 2002 Dec 15; 62(24):7195-9.
Score: 0.011
-
Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood. 2003 Mar 01; 101(5):1718-26.
Score: 0.011
-
Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma. Cancer Res. 2002 Feb 15; 62(4):1123-8.
Score: 0.011
-
Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus--positive Hodgkin's lymphoma. Int J Cancer. 2001 Sep 01; 93(5):706-13.
Score: 0.010
-
A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood. 2001 Aug 15; 98(4):1166-73.
Score: 0.010
-
Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter. Cancer Gene Ther. 2000 Aug; 7(8):1120-6.
Score: 0.010
-
Gene therapy in a rodent model of Parkinson's disease using differentiated C6 cells expressing a GFAP-tyrosine hydroxylase transgene. Life Sci. 1999; 65(5):483-91.
Score: 0.009
-
Selective killing of glioma cell lines using an astrocyte-specific expression of the herpes simplex virus-thymidine kinase gene. Cancer Res. 1998 Oct 15; 58(20):4577-80.
Score: 0.009
-
Increased transduction efficiency of primary hematopoietic cells by physical colocalization of retrovirus and target cells. J Hematother. 1998 Jun; 7(3):217-24.
Score: 0.008
-
High-efficiency transduction of freshly isolated human tumor cells using adenoviral interleukin-2 vectors. Hum Gene Ther. 1996 Jun 20; 7(10):1233-9.
Score: 0.007
-
Molecular analysis of retroviral transduction in chronic myelogenous leukemia. Hum Gene Ther. 1991; 2(4):317-21.
Score: 0.005
-
A downstream initiation element required for efficient TATA box binding and in vitro function of TFIID. Nature. 1990 Nov 01; 348(6296):86-8.
Score: 0.005
-
Transfection and gene expression in normal and malignant primary B lymphocytes. J Immunol Methods. 1990 Oct 04; 133(1):77-85.
Score: 0.005
-
Rapid expression of protooncogenes c-fos and c-myc in B-chronic lymphocytic leukemia cells during differentiation induced by phorbol ester and calcium ionophore. Blood. 1989 May 01; 73(6):1656-63.
Score: 0.004